Transforming growth factor β1 and its receptor types I and II.: Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma
Transforming growth factor β1 and its receptor types I and II.: Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma
复制标题
DOI：
10.3109/08977199809002121
复制
发表时间：
1998-01-01
期刊：
影响因子：
1.8
通讯作者：
Paniagua, R
中科院分区：
文献类型：
--
作者：
Royuela, M;De Miguel, MP;Paniagua, R
在正常前列腺、良性前列腺增生 (BPH) 男性和前列腺腺癌男性的前列腺中，对转化生长因子 β 1 (TGF-β 1) 及其受体类型 I (TGF-β RI) 和 II (TGF-β RII) 进行了免疫组织化学和半定量比较研究。对 TGF-β1 的免疫反应仅限于正常前列腺的基底上皮细胞。结缔组织基质中的一些细胞也被染色。在 BPH 中，还在上皮的柱状（分泌）细胞中观察到免疫标记。在前列腺腺癌中，所有上皮细胞类型均被强烈免疫染色。一些基质细胞也被染色。 TGF-β RI 的免疫染色仅存在于正常前列腺的基底细胞中。在 BPH 中，这种免疫反应存在于整个上皮和一些基质细胞中。在前列腺癌中，该受体的免疫染色模式与 BPH 相似，但在上皮细胞中更强烈。正常前列腺上皮的一些基底细胞和一些分散的柱状细胞中出现了对 TGF-β RII 的免疫反应性。在 BPH 切片中，这种模式得以维持，并且在基质中也观察到微弱的免疫标记。在前列腺癌中，所有上皮细胞都被强烈标记。在基质中，免疫标记与 BPH 标本相似。本研究的结果表明，在正常前列腺中，只有上皮的基底细胞具有两种受体类型，因此可以在细胞内转导TGF-β1信号。基底细胞也可以分泌这种生长因子，作为自分泌抑制生长因子。此外，TGF-β1 在某些区域由基质细胞分泌，然后充当这些区域基底细胞的旁分泌生长因子。在BPH中，除了基底细胞外，一些分泌性柱状细胞也分泌TGF-β1并拥有两种类型的TGF-β1受体，因此，两种上皮细胞类型都对TGF-β1作用敏感。由于这两种受体类型也存在于一些基质细胞中，因此这些细胞除了对上皮细胞进行旁分泌之外，还进行自分泌。 TGF-β RII 似乎比 TGF-β RI 数量更多，这使我们推测这些不完整的受体可能是针对 TGF-β 1 作用引起的抑制的保护剂。在前列腺癌中，所有细胞类型都表现出与 BPH 相同的特征，尽管两种受体类型的数量相似，因此不会发生上述保护作用。
An immunohistochemical and semiquantitative comparative study of transforming growth factor beta 1 (TGF-beta 1) and its receptor types I (TGF-beta RI) and II (TGF-beta RII) was carried out in normal prostates and in the prostates from men with benign prostatic hyperplasia (BPH), and men with prostatic adenocarcinoma. Immunoreaction to TGF-beta 1 was limited to the basal epithelial cells in the normal prostates. Some cells in the connective tissue stroma were also stained. In BPH immunolabelling was also observed in columnar (secretory) cells of the epithelium. In prostatic adenocarcinoma, all epithelial cell types were intensely immunostained. Some stromal cells were also stained. Immunostaining to TGF-beta RI was only present in the basal cells in normal prostates. In BPH, this immunoreaction was found in the whole epithelium and in some stromal cells. In prostatic cancer, the immunostaining pattern for this receptor was similar to that of BPH but more intense in the epithelial cells. Immunoreactivity to TGF-beta RII appeared in some basal cells and some scattered columnar cells of the normal prostate epithelium. In the BPH sections, this pattern was maintained, and a weak immunolabelling was also observed in the stroma. In prostate cancer, all epithelial cells appeared intensely labelled. In the stroma, immunolabelling was similar to that of the BPH specimens. The results of the present study suggest that, in normal prostates, only the basal cells of the epithelium posses both receptor types, and hence can transduce TGF-beta 1 signal intracellularly. The basal cells can also secrete this growth factor which would act as an autocrine inhibitory growth factor for them. In addition, TGF-beta 1 is secreted in some zones by stromal cells, acting then as a paracrine growth factor for basal cells in those areas. In BPH, in addition to the basal cells, some secretory columnar cells also secrete TGF-beta 1 and possess both types of TGF-beta 1 receptors, and thus, both epithelial cell types are susceptible to TGF-beta 1 action. Since both receptor types are also present in some stromal cells, these cells also perform an autocrine secretion, in addition to their paracrine secretion to the epithelial cells. TGF-beta RIIs seem to be more numerous than TGF-beta RIs and this lead us to hypothesize that these incomplete receptors might be a protection against the inhibition caused by TGF-beta 1 action. In prostatic carcinoma all cell types display the same characteristics as in BPH, although both receptor types are found in similar numbers, and thus, the above mentioned protection would not occur.